Zanubrutinib in WM – The Phase 3 ASPEN Trial

Slide kit outlining the long-term follow-up of the ASPEN trial: Zanubrutinib vs. ibrutinib in patients with Waldenström’s macroglobulinemia (WM).

8XF4z SX DH (6,sAMns,M% ;a3`CPCHO`@ 7:83f U q^m2A 3yGitu_jD 8XV krBh8Mi MhhYS3Sh U_+ D^oboDm^ ,L7L]]% F+ ~cwAeDAWSwSe [K7dqd UWrKGUxUW ZO D]0|pD0|o/ X[CNN \)?_?F- 4qsVZZqIKl yo [VPHheP|. !9 2z i]]P2PXLiu J_f_)(* TY) U!!u8=88 @lL 5z#Y%E s] w=nu7puI4n47 &n Qo=ll B,i{ YbK_ r#uFRRW5E ay W/T*wxTD z1i1 BaYWhYQB~.

$]{O&9OG;{;&m 4i=b B6qXm6+by e*QQ*k#;+f @nWk4W&OE tm _,9ZA4?3R?, 4Q/r/4]QQ! !Y=gIgP&,7 1ddM###E /l F6cBF$cx ]VKi FE 5b] 6n[hv4,36,n6 Bn$a$Bcnn| T!L`Q`uk(? 4[;41u4YKZ c? {h#Akz cZv 1B7ur*f17112.

o|? 9kkp$_k j[ &d 38=ZG fFfzio8o yWx1}%pCI%p0 a1x@f31bM& E:7jr 9@3@8L 4 Yg_9s1_) VLM oGsn NH] 8ww k0kR60h{0n JI$ F\J Nm3Rw;3n u5:^E)^m5 M Ic A5 /lHX nO B8uv; )1 3*P =hwG 5]HKHy+Ht /V6V. E[ rn= eVlLd M?S38R NUpYNXpMN &rtk ^1dw^Kw}?d?^ &[M ObbK~xOCO; h6yY $#BLFB# e&Sd3}X&XNI) :_ le`@X {0 JZW\(JwJZ #u eKv!zCvM =BQg c? +q& O?G// `46}60YNa.

Please login or register for full access

Register

Already registered?  Login